July 20 | 2022
Kallelse till extra bolagsstämma i 2curex AB
Read more
July 20 | 2022
Notice of extra general meeting in 2cureX AB
Read more
July 1 | 2022
Dr. Raphael Gruber joins 2cureX as new Medical Director
Read more
June 28 | 2022
2cureX expands distribution of IndiTreat® to Israel
Read more
June 7 | 2022
2cureX AB announces share purchase by the company’s Chairman of the Board of Directors and Executive Management
Read more
May 31 | 2022
Strengthening the IndiTreat® distribution in North Europe
Read more
May 24 | 2022
Kommuniké från årsstämma i 2cureX AB
Read more
May 24 | 2022
2cureX publishes interim report for the first quarter 2022
Read more
May 24 | 2022
2cureX offentliggör delårsrapport för det första kvartalet 2022
Read more
May 20 | 2022
We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022
Read more
May 17 | 2022
Three IndiTreat® posters have been accepted at ESMO-GI 2022
Read more
May 12 | 2022
2cureX AB nominates Dr. Michael Schaefer to the Board of Directors
Read more
May 12 | 2022
2cureX AB nominerar Dr. Michael Schaefer till styrelsen
Read more
May 11 | 2022
IGNITE update – Eight hospitals have been enrolled in the program
Read more
May 9 | 2022
2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine
Read more
May 6 | 2022
2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share
Read more
May 6 | 2022
2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie
Read more
May 5 | 2022
Redeye research interview with 2cureX CEO, Fernando Andreu
Read more